Our Experience and Literature Update Regarding Concomitant Radiotherapy with CDK4/6 Inhibitors and Hormonal Therapy in Metastatic Breast Cancer
Background and Objectives: Standard treatment in metastatic breast cancer with positive estrogen receptors and negative HER2neu is represented by CDK4 inhibitors combined with aromatase inhibitors or fulvestrant. Palliative radiotherapy is indicated for symptoms or local–regional control. Multiple p...
Saved in:
| Main Authors: | Laura-Florentina Rebegea, Dorel Firescu, Oana-Gabriela Trifanescu, Roxana-Andreea Rahnea-Nita, Liviu Bilteanu, Mihaela Dumitru, Florentina Lacatus, Gabriela Rahnea-Nita |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Journal of Mind and Medical Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2392-7674/12/1/33 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The role of radiotherapy in the complex treatment of mycosis fungoides; a case report
by: Laura Florentina Rebegea, et al.
Published: (2024-04-01) -
Assessment of psycho-emotional symptoms in cancer patients in an Oncology-Palliative Care Department from Romania
by: Roxana Andreea Rahnea-Nita, et al.
Published: (2024-10-01) -
Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 Inhibitors
by: Zehra Sucuoğlu İşleyen, et al.
Published: (2025-07-01) -
Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study
by: Seda Kahraman, et al.
Published: (2024-12-01) -
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them
by: L. Foffano, et al.
Published: (2025-02-01)